REYATAZ 50mg/1.5G powder for oral solution medication leaflet

J05AE08 atazanavir • Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors

Atazanavir is an antiretroviral medication used for the treatment of human immunodeficiency virus (HIV) infection. It belongs to the class of protease inhibitors and works by blocking the HIV protease enzyme, which is essential for viral replication. By inhibiting this enzyme, atazanavir reduces viral load and helps maintain immune system function.

Atazanavir is administered orally, usually once daily, in combination with other antiretroviral medications as part of highly active antiretroviral therapy (HAART). It is recommended to be taken with food to improve absorption.

Common side effects include nausea, jaundice, headaches, abdominal pain, and skin rashes. In rare cases, severe adverse reactions such as liver impairment, severe hyperbilirubinemia, or allergic reactions may occur.

Patients taking atazanavir should undergo regular monitoring for liver function and bilirubin levels. Additionally, the medication may interact with other drugs, requiring caution. Atazanavir is an important component of HIV treatment, contributing to improved quality of life for patients living with the virus.

General data about REYATAZ 50mg/1.5G

Substance: atazanavir

Date of last drug list: 01-07-2013

Commercial code: W14089001

Concentration: 50mg / 1.5g

Pharmaceutical form: powder for oral solution

Quantity: 1

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Pharmaceutical forms available for atazanavir

Concentrations available for atazanavir

100mg, 150mg, 200mg, 300mg, 50mg/1.5g

Combinations with other substances